| Literature DB >> 31806721 |
Maximilian Ackermann1,2,3, Helge Stark4,3, Lavinia Neubert4,5, Stephanie Schubert4, Paul Borchert4, Friedemann Linz6, Willi L Wagner7,8, Wolfram Stiller7,8, Mark Wielpütz7,8, Anne Hoefer4, Axel Haverich5,9, Steven J Mentzer10, Harshit R Shah4,5, Tobias Welte5,11, Mark Kuehnel4,5,3, Danny Jonigk4,5,3.
Abstract
The pathogenetic role of angiogenesis in interstitial lung diseases (ILDs) is controversial. This study represents the first investigation of the spatial complexity and molecular motifs of microvascular architecture in important subsets of human ILD. The aim of our study was to identify specific variants of neoangiogenesis in three common pulmonary injury patterns in human ILD.We performed comprehensive and compartment-specific analysis of 24 human lung explants with usual intersitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and alveolar fibroelastosis (AFE) using histopathology, microvascular corrosion casting, micro-comupted tomography based volumetry and gene expression analysis using Nanostring as well as immunohistochemistry to assess remodelling-associated angiogenesis.Morphometrical assessment of vessel diameters and intervascular distances showed significant differences in neoangiogenesis in characteristically remodelled areas of UIP, NSIP and AFE lungs. Likewise, gene expression analysis revealed distinct and specific angiogenic profiles in UIP, NSIP and AFE lungs.Whereas UIP lungs showed a higher density of upstream vascularity and lower density in perifocal blood vessels, NSIP and AFE lungs revealed densely packed alveolar septal blood vessels. Vascular remodelling in NSIP and AFE is characterised by a prominent intussusceptive neoangiogenesis, in contrast to UIP, in which sprouting of new vessels into the fibrotic areas is characteristic. The molecular analyses of the gene expression provide a foundation for understanding these fundamental differences between AFE and UIP and give insight into the cellular functions involved.Entities:
Mesh:
Year: 2020 PMID: 31806721 DOI: 10.1183/13993003.00933-2019
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671